USE OF VALSARTAN-SACUBITRIL IN ELIGIBLE SYSTOLIC HEART FAILURE PATIENTS

Autor:	Yashu Dhamija, David C. Kaelber
Rok vydání:	2020
Předmět:	medicine.medical_specialty Ejection fraction business.industry medicine.disease Sacubitril Valsartan Heart failure Internal medicine Renin–angiotensin system medicine Cardiology Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Journal of the American College of Cardiology. 75:765
ISSN:	0735-1097
DOI:	10.1016/s0735-1097(20)31392-9
Popis:	Due to benefits in mortality and morbidity, angiotensin receptor-neprilysin inhibitors (ARNI) are now recommended in the management of patients with chronic heart failure with a reduced ejection fraction. Due this recent update in guidelines, we sought to investigate the percentage of eligible
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0b49e7e7f24401ccef939ba33a21f522 https://doi.org/10.1016/s0735-1097(20)31392-9 Zobrazit plný text záznamu